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Next-generation sequencingAbstract Understanding tumor diversity has been a long-lasting and challenging question for
researchers in the field of cancer heterogeneity or tumor evolution. Studies have reported that com-
pared to normal cells, there is a higher genetic diversity in tumor cells, while higher genetic diversity
is associated with higher progression risks of tumor. We thus hypothesized that tumor diversity also
holds true at the gene expression level. To test this hypothesis, we used t-test to compare the means
of Simpson’s diversity index for gene expression (SDIG) between tumor and non-tumor samples.
We found that the mean SDIG in tumor tissues is significantly higher than that in the
non-tumor or normal tissues (P< 0.05) for most datasets. We also combined microarrays and
next-generation sequencing data for validation. This cross-platform and cross-experimental
validation greatly increased the reliability of our results.Introduction
Cancer is a group of diseases characterized by uncontrolled
division of abnormal cells [1]. Normal cells grow and divide
in a controlled way; however, gene mutations can conferabnormal cells that no longer divide and reproduce in an
orderly manner. Mutations in abnormal cells could activate
oncogenes and inhibit tumor suppressors, thereby disrupting
the normal balance between the two opposing processes of cell
birth and cell death [2]. Most normal cells in tissues undergo
programed cell death, called apoptosis, if detached from their
neighboring cells. However, the self-destruct processes in can-
cer cells do not work; therefore, cancer cells are able to spread
to other sites in the body (so-called metastasis) [3]. Cancer cells
face selective pressure from their surrounding microenviron-
ment that favors the survival of the fittest, which would be
linked to the metastatic potential [4,5].
Although human evolution and cancer progression are not
identical, if cancer is considered in terms of evolution on af China.
378 Genomics Proteomics Bioinformatics 13 (2015) 377–382small time and spatial scale, a tumor cell population can be
regarded as constantly evolving under natural selection [6].
For example, human evolution is driven by mutations in a
gamete [7], while cancer is caused by mutations in the DNA
of somatic cells; human evolution is a process of billions of
years, while cancer progression occurs within the timescale of
a human lifetime [8]. Maley et al. reported an evolutionary
approach to characterize the diversity within a cell population
in Barrett’s esophagus lesions [6]. They found that the
increased diversity of tumor cells is strikingly correlated with
the progression from normal cell to cancer [9]. On the one
hand, tumor progression can be viewed as a sequential selec-
tion for fitter or dominant clones; on the other hand, tumors
with greater genetic clonal diversity have a high probability
of generating mutant cells, driving the transformation from
the non-tumor to the tumor state [9,10]. Cancer evolution is
a reiterative process, which consists of clonal expansion,
genetic diversification, and clonal selection, in the adaptive
landscapes of tissue ecosystems [11].
Biodiversity is defined as the ‘‘variation of life at all levels
of biological organization” [12], which not only involves the
number of species, but also the number of individuals within
each species. Diversity can be measured by Simpson’s diver-
sity index (SDI), which takes into account the number of
species and the abundance of each species. In this study,
we applied the SDI to estimate the gene expression diversity
in hepatocellular carcinoma (HCC) cells and its adjacent
normal tissues.
HCC, the main type of primary liver cancer, is the most
common cancer in some parts of the world [13] with rising
incidence in the United States. The American Cancer Society
estimated that about 35,660 people in the U.S. would be
diagnosed with HCC, and about 24,550 people would die of
the cancer in 2015 [14].Table 1 Main characteristics of datasets examined in the current study
Dataset Platform
No. of tissue samples Data
removed (%)
No. of
replicates
average
(range)
Total Tumor Normal
GSE5093 Microarray 40 20 20 1.24 38 (3–40)
GSE3500 Microarray 181 105 76 9.86 172 (3–180
GSE4024 Microarray 196 98 98 9.83 192 (3–196
GSE1898 Microarray 364 182 182 8.31 360 (3–364
GSE65484 aCGH 28 14 14 0
GSE65485 NGS 55 50 5 0
Note: aCGH, array-based comparative genomic hybridization; NGS, nex
chronous adrenal metastasis.In this study, we first defined the proportion of positive
sample (PPS) and the proportion of positive pair number
(PPPN) of Simpson’s diversity index for gene expression
(SDIG), and then a two-sample, one-sided t-test was per-
formed to find out whether there was a significant difference
in the mean SDIG between non-tumor and tumor tissues.
We also combined microarray and the next-generation
sequencing (NGS) data, which allows compensation, and cross
validation of results obtained. Generally, microarrays are con-
sidered easier to use with less labor-intensive and less compli-
cated sample preparation processes than those in NGS,
whereas RNA-Seq technology offers better gene/transcript
coverage. ‘‘In reality the two technologies couldn’t be more
complementary”, as commented by Scott Peterson at J. Craig
Venter Institute. The low cost, short turn-around time, excep-
tional quantitative accuracy, and ease of data generation all
make the microarray the clear choice for gene expression study
[15], to complement NGS studies.Materials and methods
Data sources
We obtained six datasets by searching the Gene Expression
Omnibus (GEO) [16] in 2015. These include (1) GSE5093 con-
sisting of 20 normal and 20 tumor samples [17], (2) GSE3500
consisting of 76 non-tumor samples and 105 primary liver
tumor samples [18], (3) GSE4024 consisting of 98 normal
and 98 tumor samples [19], (4) GSE1898 consisting of 182 nor-
mal and 182 tumor samples [20], (5) GSE65484 consisting of
14 HCC patients and 14 paired adjacent normal samples
[21], and (6) GSE65485 consisting of 50 HCC patients and 5
normal samples [21] (Table 1).Note Ref.
Tumor samples and the corresponding non-cancerous adjacent
hepatic tissues came from two HCC patient groups, i.e., MIM
with primary HCC and venous metastasis and MAM with HCC
but no detectable metastasis
[17]
) The dataset included expression data in more than 200 samples.
105 tumor samples from 82 HCC patients with primary HCC
and 76 non-tumor samples from 72 controls were analyzed in
this study for genes that were shared by all the 181 samples
[18]
) RNA from 19 normal liver samples was pooled as reference for
all microarray experiments. At least two hybridizations were
carried out to obtain gene expression profile data for each of the
49 HCC tissues
[19]
) RNA from 18 normal liver samples was pooled as reference for
gene expression profiles from 91 human HCC tissues. Two
hybridizations were performed for each of the 91 HCC tissues
[20]
The dataset included 50 HCC patients and 14 paired adjacent
tissues We only used the 14 pairs of HCC and normal tissues for
our study
[21]
Whole transcriptome sequencing profiling was performed for 50
HCC samples and 5 adjacent normal samples
[21]
t-generation sequencing; MIM, missing in metastasis; MAM, meta-
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We first extracted gene expression values from the six datasets.
In datasets GSE5093, GSE4024, and GSE1898, HCC and non-
tumor sample were paired as channel 1 or channel 2. Mean
intensity of each channel was calculated as shown below.
ch1d mean ¼ ch1i mean ch1b median ð1Þ
ch2d mean ¼ ch2i mean ch2b median ð2Þ
where, ch1i_mean and ch2i_mean are the uncorrected mean
pixel intensity for channel 1 and channel 2, respectively;
ch1b_median and ch2b_median are the median background
pixel intensity for channel 1 and channel 2, respectively.
In the dataset GSE3500, the ratio of the intensity value in
each sample to that in the reference sample was taken as its
gene expression value. For example, if channel 1 is reference
and channel 2 is sample (non-tumor or HCC), the gene expres-
sion value is ch2d_mean/ch1d_mean.
Next, if the signal quality was good, the flag value was set
to 0, whereas flag values were set as 100 for poor signals and
50 for no signals. All non-flagged (flag value = 0) array ele-
ments with fluorescence intensities in each channel 1.5 times
greater than the local background were considered well-
measured, and all flagged (flag value = 50 or 100) array
elements were removed.
Lastly, to eliminate noise and possible artifacts, we
removed the genes for which measurements did not contain
at least two replicates across the dataset (Table 1). Then, impu-
tation was performed to eliminate the imbalance for the large
ranges of the replicates.
The processed data were downloaded directly for NGS
and aCGH analyses. We inversely transformed the log-
transformed values in GSE65484 and used the fragments per
kilobase million (FPKM) values in GSE65485 as gene expres-
sion values.
Gene expression diversity index
Biodiversity indices represent the commonness and rarity of
species in a community. The ability to measure diversity in this
way enables biologists to understand the community structure.
SDI [22] is defined as
D ¼ 1
XS
i¼1
p2i ; ð3Þ
where D refers to the Simpson’s index of diversity, S is the
total number of species, and pi represents the proportion of
the ith species.
The pi can be calculated by
pi ¼
ni
N
¼ niPS
1ni
; ð4Þ
where ni is the number of individuals in the ith species and N is
the total number of individuals in all the species.
We adapted three indices of diversity from the SDI in
ecology and evolutionary biology into our study: gene number
(S), proportion of expression value of gene i in relative to the
total expression value of all genes (pi), and SDI for gene
expression (D).SDIG (D) is a simple mathematical measurement that char-
acterizes gene expression diversity in a sample. pi is calculated
by the following equation
pi ¼
giPS
1gi
; ð5Þ
where gi is the expression value of the ith gene.
The squared proportions for all the genes are summed, sub-
tracted from 1, and then SDIG (D) is calculated using equation
(3). The index value ranges from 0 to 1; the greater the value is,
the greater the gene expression diversity of sample is.
Let DTj be the SDIG of the jth sample in tumor tissue
(j= 1,2,. . .N) and DNk be the SDIG of the ith sample in
non-tumor or normal tissue (k= 1,2,. . .M). The total number
of pairs (DTj, DNk) is M  N.
We define the positive pair of SDIG as those pairs of which
SDIG in tumor tissue is greater than that in non-tumor or nor-
mal tissue.
The PPPN of SDIG relative to the total number of pair
(DTj, DNk) is calculated by
T ¼ Q
MN ; ð6Þ
where Q is the positive pair number of SDIG.
Statistical analysis
A two-sample, one-sided t-test was performed to determine
whether the mean SDIG in tumor tissues is greater than that
in non-tumor or normal tissues. P values were determined by
Welch’s t-test and differences are considered significant with
P< 0.05.
Results and discussion
The main purpose of this study was to test the hypothesis that
the mean SDIG in HCC tumor tissues is higher than that in
non-tumor or normal tissues. To do this, we first searched
the GEO, the online resource for gene expression data, using
the keyword ‘‘HCC” or ‘‘primary liver cancer”, and retrieved
six HCC-related datasets. These include GSE5093 [17],
GSE3500 [18], GSE4024 [19], GSE1898 [20], GSE65484 [21],
and GSE65485 [21]. Then, we defined the SDIG, PPS, and
PPPN. Lastly, we used t-test to compare the mean SDIG
between HCC tumor and non-tumor or normal tissues.
We defined PPS for these datasets, in which the gene
expression diversity of primary liver tumor channel is greater
than that of the non-tumor channel. No PPS was calculated
for GSE3500 and GSE65485 datasets, since non-tumor sam-
ples were not paired with HCC samples. Alternatively, we cal-
culated the PPPN by SDIG and employed t-test to compare
gene expression diversity between the non-tumor and HCC
samples.
Gene expression diversity in both non-tumor (normal) and
HCC tumor tissues for the six datasets is shown in Figure 1.
Median SDIG in tumor tissue is greater than that in
non-tumor or normal tissues for GSE5093, GSE3500,
GSE1898, GSE65484, and GSE65485. Table 2 shows that all
the PPPN of SDIG are greater than 50%. The mean T (PPPN)
value is 72%, which is nearly 3 times as much as the
proportion of the negative pair number (PNPN) (28%). PNPN
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Figure 1 Gene expression diversity of HCC tumor and non-tumor samples in the six datasets examined
Boxplot of gene expression diversity for GSE5093 (A), GSE3500 (B), GSE4024 (C), GSE1898 (D), GSE65484 (E), and GSE65485 (F),
respectively. The median expression diversity is indicated with horizontal line. The boxplot shows minimum, first quartile, median, third
quartile, and maximum from bottom to top. The gene expression diversity was calculated using equations (3)–(5).
380 Genomics Proteomics Bioinformatics 13 (2015) 377–382represents the proportion of the pairs in which SDIG of
tumor tissue is not greater than that in non-tumor or normal
tissue, relative to the total number of pairs. This result indi-
cates that for a majority of sample pairs, the gene expression
diversity in HCC samples is greater than that in non-tumor
samples.
We lastly used the t-test to determine whether the mean of
SDIG in tumor tissue is greater than that in the non-tumor or
normal tissue. It was shown that except for the GSE4024, gene
expression diversities in tumor tissues were significantly higher
than those in non-tumor or normal tissues in all the other five
datasets (P< 0.05). In particular, highly significant gene
expression diversities were observed for GSE5093, GSE1898,
and GSE65485 (P< 0.01). Datasets GSE4024 and GSE1898
came from the same lab with same RNA preparation and
microarray procedure [19,20], but contained different numbers
of samples. There were 196 and 364 samples for GSE4024 andTable 2 Gene expression diversity in HCC and normal samples of dat
Dataset Data structure PPS (%) Q T
GSE5093 Paired 100 343 86
GSE3500 Non-paired NA 5150 65
GSE4024 Paired 61.2 5283 55
GSE1898 Paired 67.2 19,543 59
GSE65484 Paired 85.7 146 74
GSE65485 Non-paired NA 238 95
Mean 72
Note: GSE3500 and GSE65485 are not paired and PPS can’t be calculate
proportion of positive pair number (PPPN) of SDIG relative to the to
carcinoma; PPS, proportion of positive sample; NA, not available; SDIG,
statistical analysis and differences between HCC and normal samples areGSE1898, respectively. We speculate that the smaller sample
size in GSE4024 could partially explain the different observa-
tions between these two datasets, since the confidence in the
hypothesis increases when the sample size increases.
According to the aforementioned PPPN and t-test analyses
for gene expression diversity in both non-tumor and HCC
tumor tissues, we found greater gene expression diversity in
HCC tumor samples than the non-tumor samples. This obser-
vation is consistent with previous finding [23]. Using
sequencing-based gene expression profiles (SAGE-seq), Wu
et al. tested the gene expression diversity in breast cancer
and found that breast cancer samples have higher diversity
than that from normal samples [23]. Different from their study
on breast cancer samples, our study on the same assumption is
exclusively focused on HCC. Secondly, only 14 samples were
included in their study, while we tried to collect as many
HCC samples as possible from publically available repositoriesasets examined in the current study
(%)
Mean gene expression diversity
P value
Normal HCC
0.9996 0.9997 3.756E05*
0.9894 0.9918 0.0178*
0.9996 0.9996 0.1034
0.9995 0.9995 0.0032*
.5 0.9420 0.9861 0.0495*
.2 0.9862 0.9927 0.0018*
d. Q indicates the positive pair number of SDIG, and T indicates the
tal number of tumor and normal SDIG pairs. HCC, hepatocellular
Simpson’s diversity index for gene expression. t-test was performed for
considered significant with P< 0.05 (*).
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the 423 liver cancer samples in TCGA provided only level 3
data, which contain normalized read counts instead of gene
expression value, we didn’t include any TCGA datasets to
our study. As a result, we collected six GEO datasets (totally
864 samples) for HCC gene expression data from HCC and
adjacent non-tumor samples. Thirdly, their conclusion was
based on Wilcoxon rank-sum test’s P value of 0.07284, which
is in the borderline of significance due to limited number of
samples, while in our study, validation based on the cross-
platform and cross-experiment largely increases reliability for
our study and we chose more stringent significances value of
0.05 and 0.01 as cutoff.
Testing the gene expression diversity in HCC is a first-time
study up to now. Further experiments on this may lead to bet-
ter understanding of the relationship between increased gene
expression diversity and the processes involved in cancer pro-
gression from non-tumor to tumor in HCC. There is a high
probability that the diversely expressed tumor gene causes
uncontrolled gene pathway regulation [24], which may drive
the transformation from non-tumor to HCC.
Moreover, ‘‘the more evenly distributed gene expression,
the higher its diversity” [25]. Gene expression in normal liver
cells may be distributed randomly [26]. However, it may
become more evenly distributed in HCC; that is, functionally
important genes may be expressed as equally as the ubiquitous
genes in the progression from non-tumor to HCC. A more
evenly distributed expression of oncogenes and tumor suppres-
sors may trigger cancer by disturbing the normal balance
between cell mitosis and apoptosis [27]. Measurement of gene
expression diversity may assist in finding biomarkers for can-
cer risk and progression from non-tumor to HCC, through
the accumulation of evenly-expressed genes.
One limitation of the current study is that gene ontology
(GO) and pathway analyses were not performed. In the future,
we will look into the pathways, gene sets, or modules to under-
stand if higher gene expression diversity is concentrated in cer-
tain cellular pathways or more conserved in certain pathways.Conclusion
HCC is the most common cancer and the leading cause of death
in some parts of the world. In this study, we applied the diversity
index used in themeasurement of biodiversity to gene expression
of non-tumor and HCC samples, for six datasets obtained from
GEO. We used PPS, PPPN of SDIG, and a two-sample, one-
sided t-test to prove that gene expression diversity in HCC
samples is higher than that in non-tumor samples.
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